NICE endorses only approved treatment for ultra-rare Wolman disease for children diagnosed under the age of two: Interview Opportunity

NICE endorses only approved treatment for ultra-rare Wolman disease for children diagnosed under the age of two: Interview Opportunity

Related Keywords

Manchester ,United Kingdom ,Japan ,Uxbridge ,Hillingdon ,Canada ,Cambridge ,Cambridgeshire ,London ,City Of ,Massachusetts ,United States ,Altrincham ,Trafford ,Boston ,Wythenshawe ,Akanuma ,Tochigi ,Canadian ,Sean Richardson ,Bob Stevens ,Anna Clark ,Simon Jones ,National Health Service ,University Dental Hospital Of Manchester ,Astrazeneca ,Nasdaq ,Manchester University ,Department Of Health ,European Medicines Agency ,Saint Mary Managed Clinical Service ,European Union ,Alexion Pharmaceuticals Inc ,Foundation Trust ,National Institute For Health ,Syneos Health ,Care Research ,National Institute ,Care Excellence ,Wolman Disease ,Paediatric Inherited Metabolic Disease ,Clinical Research Facility ,Royal Manchester Children ,Vice President ,General Manager ,Group Chief Executive ,Astrazeneca Rare Disease ,Alexion Pharmaceuticals ,Rare Diseases ,Manchester Royal Infirmary ,Saint Mary ,Managed Clinical Service ,Manchester Royal Eye Hospital ,University Dental Hospital ,Trafford General Hospital ,Altrincham Hospital ,Wythenshawe Hospital ,Withington Hospital ,North Manchester General ,United Kingdom Aid ,Last Accessed Nov ,Liver Journal ,Canadian Liver Journal ,Kanuma Summary ,